The FDA has accepted AbbVie's supplemental Biologics License Application (sBLA) for BOTOX Cosmetic to treat masseter muscle prominence, the first neurotoxin indication for this specific aesthetic concern. The acceptance signals FDA agreement that the data package supports review, moving the indication toward a potential approval decision.
Regulatory
FDA Accepts BOTOX Cosmetic sBLA for Masseter Prominence
AbbVie's BOTOX Cosmetic wins FDA acceptance for masseter muscle prominence—first and only neurotoxin indication if approved.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |